Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 E* A# E$ I u# f' K) g: J$ n- yNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
0 B( S" ]8 R; h/ F! y+ Author Affiliations+ h2 [: Z8 F; E- u; ?& c3 X- G* z
" y( Y. Z4 u, g" ~1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) X6 d9 Z% r8 T3 Y0 M: ]8 ]
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
. i! u+ A! b% V( `: V. U! [3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 F9 ^) L n: L4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
8 x- e( I2 {1 I+ R5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, [' a' j: b- h* A) C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 3 h6 x8 G8 t3 `1 J* ?4 u% h
7Kinki University School of Medicine, Osaka 589-8511, Japan
! d* d B) A7 [' v% C3 r: e% y8Izumi Municipal Hospital, Osaka 594-0071, Japan
, W$ @3 }+ T9 `9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ I% U3 P$ e- c7 [3 q8 XCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; j% O7 B6 p# U1 w" I
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 a8 L5 [( o g0 P! J! b
# X( f) Y5 F" P9 Y* B |